Skip to main content

Table 2 Summary of results from the base-case analysis (discounted)

From: A cost-effectiveness analysis of ruxolitinib versus best alternative therapy for patients with steroid-refractory chronic graft-versus-host disease aged > 12 years in Singapore

 

RUX

BAT

Incremental

LYs

10.28

9.42

0.86

QALYs

7.31

6.51

0.80

Costs

SGD 303,214

SGD 302,673

SGD 540

ICER (Cost/LY)

SGD 627/LY

ICER (Cost/QALY)

SGD 677/QALY

  1. BAT, best available therapy; ICER, incremental cost-effectiveness ratio; LY, life year; QALY, quality-adjusted life year; RUX, ruxolitinib; SGD, singapore dollar
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us